Wall Street brokerages expect that Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) will report sales of $1.42 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aeglea BioTherapeutics’ earnings, with the lowest sales estimate coming in at $1.34 million and the highest estimate coming in at $1.50 million. Aeglea BioTherapeutics reported sales of $13.70 million in the same quarter last year, which indicates a negative year over year growth rate of 89.6%. The firm is expected to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Aeglea BioTherapeutics will report full year sales of $5.43 million for the current year, with estimates ranging from $5.00 million to $5.86 million. For the next fiscal year, analysts anticipate that the firm will post sales of $14.66 million, with estimates ranging from $10.23 million to $21.78 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Aeglea BioTherapeutics.
Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Aeglea BioTherapeutics had a negative net margin of 358.29% and a negative return on equity of 78.56%.
In other news, CEO Anthony G. Quinn acquired 67,472 shares of the business’s stock in a transaction dated Monday, March 14th. The stock was purchased at an average cost of $1.93 per share, for a total transaction of $130,220.96. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Jonathan Alspaugh bought 75,000 shares of the stock in a transaction dated Friday, March 11th. The stock was bought at an average cost of $2.08 per share, with a total value of $156,000.00. The disclosure for this purchase can be found here. Insiders bought a total of 257,328 shares of company stock valued at $545,246 over the last quarter. Company insiders own 3.80% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGLE. Suvretta Capital Management LLC lifted its stake in shares of Aeglea BioTherapeutics by 57.9% in the 1st quarter. Suvretta Capital Management LLC now owns 4,059,894 shares of the biotechnology company’s stock valued at $9,338,000 after acquiring an additional 1,488,894 shares during the last quarter. Laurion Capital Management LP lifted its stake in shares of Aeglea BioTherapeutics by 139.1% in the 4th quarter. Laurion Capital Management LP now owns 1,450,638 shares of the biotechnology company’s stock valued at $6,891,000 after acquiring an additional 844,000 shares during the last quarter. Ghost Tree Capital LLC bought a new stake in shares of Aeglea BioTherapeutics in the 1st quarter valued at about $1,579,000. Nantahala Capital Management LLC lifted its stake in shares of Aeglea BioTherapeutics by 13.8% in the 1st quarter. Nantahala Capital Management LLC now owns 3,200,593 shares of the biotechnology company’s stock valued at $7,361,000 after acquiring an additional 387,033 shares during the last quarter. Finally, Rock Springs Capital Management LP lifted its stake in shares of Aeglea BioTherapeutics by 14.8% in the 1st quarter. Rock Springs Capital Management LP now owns 1,811,425 shares of the biotechnology company’s stock valued at $4,166,000 after acquiring an additional 234,129 shares during the last quarter. 84.13% of the stock is owned by institutional investors.
Aeglea BioTherapeutics stock opened at $1.50 on Thursday. Aeglea BioTherapeutics has a 52 week low of $1.29 and a 52 week high of $8.50. The business has a 50-day simple moving average of $1.99 and a 200 day simple moving average of $3.58. The stock has a market cap of $75.63 million, a price-to-earnings ratio of -1.38 and a beta of 1.60.
Aeglea BioTherapeutics Company Profile (Get Rating)
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.
- Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.